He threw out the verbiage that some potential products are down to market size of Loxapine. Those will not move the share price, but they could add a little more stabilization to the company. No one knows true market sizes and Elite’s potential penetration. Would be hard for analysts to create any semblance of forward PE with how little is communicated.